BioVentrix seeks SEC withdrawal of February 2026 S-1 filing

0 min read | Published on 15 Oct 2026, 12:06 AM |Updated on 15 Oct 2026, 12:06 AM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

BioVentrix, Inc. filed a request to withdraw its Form S-1 registration statement (File No. 333-293418)
The original S-1 was filed with the SEC on February 12, 2026
No securities were sold because the registration statement was never declared effective
The company requests fee credits under Rule 457(p) for future filings

*this image is generated using AI for illustrative purposes only.

BioVentrix, Inc. has requested that the Securities and Exchange Commission (SEC) consent to the withdrawal of its Registration Statement on Form S-1. The company filed this request pursuant to Rule 477 of the Securities Act of 1933.

The original registration statement, identified by File No. 333-293418, was initially submitted to the Commission on February 12, 2026. BioVentrix seeks withdrawal as of the date of the request or at the earliest practicable date thereafter.

No Securities Sold

The company confirmed that the Registration Statement was never declared effective by the SEC. Consequently, no securities were sold in connection with the offering contemplated in the filing. BioVentrix stated that withdrawing the registration is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477.

Fee Credit Request

In accordance with Rule 457(p) under the Securities Act, BioVentrix has requested that all fees paid to the Commission for the filing be credited to its account. These funds are to be offset against the filing fee for any future registration statements the company may file.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific market conditions or internal strategic shifts prompted BioVentrix to withdraw its IPO registration so soon after filing?

How might this withdrawal impact BioVentrix's timeline for future capital raises and its ability to fund ongoing medical device development?

Will the decision to withdraw signal a broader trend of biotech companies delaying public offerings amid current regulatory or valuation uncertainties?